MedTrace Logo

A Study in Patients With Mixed Dyslipidemia

NCT06497127 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 145

Last updated 2026-01-13

No results posted yet for this study

Summary

A Phase 2 in Patients With Mixed Dyslipidemia

Conditions

  • Mixed Dyslipidemia

Interventions

DRUG

BW-00112

BW-00112 or volume-matched placebo on Day 1 and Day 90

Sponsors & Collaborators

  • Shanghai Argo Biopharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yuqiong Li, Master · Shanghai Argo Biopharmaceutical Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-28
Primary Completion
2026-06-30
Completion
2028-03-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06497127 on ClinicalTrials.gov